56P Comparative analysis of HAIC combined with targeted therapy versus immunotherapy combination in advanced HCC patients with lenvatinib failure

likely to benefit from the subsequent immunochemotherapy, with a median PFS of 10.8 vs. 3.3 months (P 0.006).While prior immunotherapy didn't yield a significant effect on survival, patients with such treatment history exhibited a higher ORR (31.3 vs. 13.0%).In multivariate PFS analysis, a significant correlation was found in baseline ProGrp 300 ng/L (HR 3.0, 95%CI 1.0 -9.0).Any grade adverse events were reported in 64.1% of patients, and most experienced platelets decreased (23.1%).Conclusions: Serplulumab-based immunochemotherapy exhibits promising therapeutic efficacy for SCLC patients beyond the initial treatment phase, and further validations are warranted.